中文字幕一级黄色A级片|免费特级毛片。性欧美日本|偷拍亚洲欧美1级片|成人黄色中文小说网|A级片视频在线观看|老司机网址在线观看|免费一级无码激情黄所|欧美三级片区精品网站999|日韩av超碰日本青青草成人|一区二区亚洲AV婷婷

3月29日，WHO發(fā)布了第 55 屆藥物制劑規(guī)范專家委員會(huì)（ECSPP）技術(shù)報(bào)告TRS No.1033，其中發(fā)布了以下文件終稿：

 

Annex 1Guidelinesand guidance texts adopted by the Expert Committee on Specifications for Pharmaceutical Preparations

 

附錄1 《藥物制劑規(guī)范專家委員會(huì)通過的指南和指導(dǎo)文件》

 

Annex2Pointsto consider when including Health-Based Exposure Limits (HBELs) in cleaning validation

 

附錄2 《在清潔驗(yàn)證中應(yīng)用基于健康的暴露限度(HBELs)的考量》

 

Annex3Goodmanufacturing practices: water for pharmaceutical use

 

附錄3 《制藥用水GMP指南》

 

Annex4 Guidelineon data integrity

 

附錄4 《數(shù)據(jù)完整性指南》

 

Annex5WorldHealth Organization/United Nations Population Fund Recommendations for condom storage and shipping temperatures

 

附錄5 《WHO/聯(lián)合國人口基金關(guān)于避孕套儲(chǔ)存和運(yùn)輸溫度的建議》

 

Annex6WorldHealth Organization/United Nations Population Fund Guidance on testing of male latex condoms

 

附錄6 《WHO/聯(lián)合國人口基金關(guān)于男性乳膠避孕套測試的指南》

 

Annex7WorldHealth Organization/United Nations Population Fund guidance on conducting post-market surveillance ofcondoms

 

附錄7 《WHO/聯(lián)合國人口基金關(guān)于避孕套上市后監(jiān)測的指南》

 

Annex8WHO“Biowaiver List”: proposal to waive in vivo bioequivalence requirements forWHO Model List of Essential Medicines immediate-release,solid oral dosage forms

 

附錄8 《WHO“生物等效性清單”: 建議放棄《WHO速釋固體口服劑型基本藥物標(biāo)準(zhǔn)清單》的體內(nèi)生物等效性要求》

 

Annex9Guidelineson the implementation of the WHO Certification Scheme on the quality of pharmaceutical products moving ininternational commerce

 

附錄9 《關(guān)于實(shí)施WHO國際貿(mào)易藥品質(zhì)量認(rèn)證計(jì)劃的指南》

 

Annex10Goodreliance practices in the regulation of medical products: high level principles and considerations

 

附錄10 《醫(yī)藥產(chǎn)品監(jiān)管中的良好依賴規(guī)范：高級(jí)原則和考慮事項(xiàng)》

 

Annex11Goodregulatory practices in the regulation of medical products

 

附錄11 《醫(yī)藥產(chǎn)品監(jiān)管方面的良好監(jiān)管規(guī)范》

 

部分文件目錄如下：

 

Annex4 Guidelineon data integrity

 

附錄4 《數(shù)據(jù)完整性指南》

 

1. Introduction and background

 

介紹和背景

 

2. Scope

 

范圍

 

3. Glossary 

 

術(shù)語

 

4. Data governance

 

數(shù)據(jù)管理

 

5. Quality risk management

 

質(zhì)量風(fēng)險(xiǎn)管理

 

6. Management review

 

管理評(píng)審

 

7. Outsourcing

 

外包

 

8. Training

 

培訓(xùn)

 

9. Data, data transfer and data processing

 

數(shù)據(jù)，數(shù)據(jù)轉(zhuǎn)移和數(shù)據(jù)處理

 

10. Good documentation practices

 

良好文件記錄規(guī)范

 

11. Computerized systems

 

計(jì)算機(jī)化系統(tǒng)

 

12. Data review and approval

 

數(shù)據(jù)審核和批準(zhǔn)

 

13. Corrective and preventive actions

 

糾正和預(yù)防措施

 

References

 

參考文獻(xiàn)

 

Further reading

 

拓展閱讀

 

Appendix 1 Examples in data integrity management

 

附錄1 數(shù)據(jù)完整性管理示例

 

Annex Pointsto consider when including Health-Based Exposure Limits (HBELs) in cleaning validation

 

附錄2 《在清潔驗(yàn)證中應(yīng)用基于健康的暴露限度(HBELs)的考量》

 

1. Introduction and background

 

介紹和背景

 

2. Scope

 

范圍

 

3. Glossary

 

術(shù)語

 

4. Historical approach in cleaning validation

 

驗(yàn)證驗(yàn)證的傳統(tǒng)方法

 

5. New approach using HBELs in cleaning validation

 

使用HBEL的新方法進(jìn)行清潔驗(yàn)證

 

5.1 Documentation

 

文件

 

5.2 Equipment

 

設(shè)備

 

5.3 Cleaning agents

 

清潔劑

 

5.4 Sampling 

 

取樣

 

5.5 Cleanability studies

 

可清潔性研究

 

5.6 Risk management

 

風(fēng)險(xiǎn)管理

 

5.7 Guidance for Health-Based Exposure Limits (HBELs) setting

 

基于健康的暴露限（HBEL）設(shè)置的指南

 

5.8 Acceptance criteria

 

接受標(biāo)準(zhǔn)

 

5.9 Analytical procedures

 

分析方法

 

5.10 Data integrity

 

數(shù)據(jù)完整性

 

5.11 Cleaning validation and cleaning verification

 

清潔驗(yàn)證和清潔確認(rèn)

 

5.12 Visually clean

 

目視清潔

 

5.13 Cleaning process capability

 

清潔工藝能力

 

5.14 Personnel

 

人員

 

5.15 Life cycle

 

生命周期

 

References

 

參考文獻(xiàn)

 

Further reading

 

拓展閱讀

 

Appendix 1 Using Health-Based Exposure Limits (HBELs) to assessrisk in cleaning validation

 

附錄1使用基于健康的暴露限(HBEL)評(píng)估清潔驗(yàn)證的風(fēng)險(xiǎn)

 

此外，技術(shù)報(bào)告中提及后續(xù)GMP工作計(jì)劃：

 

Continue collaboration with the EU, EMA and PIC/S to harmonize guidanceon sterile products and, if feasible, present such guidance for possibleadoption at the next ECSPP meeting, in 2021.

 

繼續(xù)與EU、EMA和PIC/S合作，協(xié)調(diào)無菌產(chǎn)品指南，如果可行，在2021年的下次ECSPP會(huì)議上提交該指南以供可能的通過。

Continue preparation of a new IAEA/WHO text on GMP for radiopharmaceuticals forinvestigational use.

 

繼續(xù)編寫IAEA/WHO關(guān)于臨床試驗(yàn)用放射性藥品GMP的新文件。

Open the WHO guideline on cleaning validation to review, and update it inaccordance with the latest good practices, including the newly adopted Pointsto consider when including health-based exposure limits in cleaning validation.

 

啟動(dòng)WHO清潔驗(yàn)證指南的審查，并根據(jù)最新的良好實(shí)踐進(jìn)行更新，包括在清潔驗(yàn)證中使用基于健康暴露限的考量。

Publish the results of the survey of pharmaceutical manufacturers that engagein synthesis and/or production of antimicrobials on their waste and wastewatermanagement practices in a regulatory journal.

 

在監(jiān)管期刊上發(fā)表對(duì)合成和/或生產(chǎn)抗菌素的制藥商對(duì)其廢棄物和廢水管理實(shí)踐的調(diào)查結(jié)果。

 

Assist national inspectorates and manufacturers in implementing recommendationsmade in the Points to consider for manufacturers andinspectors: environmental aspects of manufacturing practices forthe preventionof AMR.

 

協(xié)助國家檢查員和制造商實(shí)施：《制造商和檢查員關(guān)于防止抗生素耐藥性的生產(chǎn)規(guī)范的環(huán)境方面的考量》。

 

Update the WHO guidance on Goodmanufacturing practices: supplemental guidelines for the manufacture ofinvestigational

pharmaceutical products for clinical trials in humans.

 

更新WHO GMP指南:人用臨床試驗(yàn)用藥生產(chǎn)補(bǔ)充指南。

Determine whether the WHO guidelines on transfer oftechnology in pharmaceutical manufacturing shouldbe updated.

 

確定是否更新WHO關(guān)于制藥技術(shù)轉(zhuǎn)移的指南。

Explore whether a new guideline is required on good practices during theresearch and development of medicinal products

 

探討是否需要制訂一個(gè)有關(guān)藥品研發(fā)過程中的良好實(shí)踐指南